# Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

> **NCT07181122** · — · RECRUITING · sponsor: **Ankara Etlik City Hospital** · enrollment: 102 (estimated)

## Conditions studied

- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

## Interventions

- **DRUG:** Androgen Receptor Pathway Inhibitors (ARPIs)

## Key facts

- **NCT ID:** NCT07181122
- **Lead sponsor:** Ankara Etlik City Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-22
- **Primary completion:** 2026-04-26
- **Final completion:** 2026-09-15
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07181122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07181122, "Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07181122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*